KR20240142470A - 지방산의 림프 방출 조성물 및 림프 혼입과 전신 질환 치료를 위한 이의 용도 - Google Patents

지방산의 림프 방출 조성물 및 림프 혼입과 전신 질환 치료를 위한 이의 용도 Download PDF

Info

Publication number
KR20240142470A
KR20240142470A KR1020247027934A KR20247027934A KR20240142470A KR 20240142470 A KR20240142470 A KR 20240142470A KR 1020247027934 A KR1020247027934 A KR 1020247027934A KR 20247027934 A KR20247027934 A KR 20247027934A KR 20240142470 A KR20240142470 A KR 20240142470A
Authority
KR
South Korea
Prior art keywords
acid
hydroxy
composition
etepa
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027934A
Other languages
English (en)
Korean (ko)
Inventor
리차드 프레스턴 메이슨
리차드 루이스 던바
Original Assignee
애머린 파마슈티칼스 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애머린 파마슈티칼스 아일랜드 리미티드 filed Critical 애머린 파마슈티칼스 아일랜드 리미티드
Publication of KR20240142470A publication Critical patent/KR20240142470A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247027934A 2022-01-26 2023-01-26 지방산의 림프 방출 조성물 및 림프 혼입과 전신 질환 치료를 위한 이의 용도 Pending KR20240142470A (ko)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202263303383P 2022-01-26 2022-01-26
US202263303365P 2022-01-26 2022-01-26
US63/303,365 2022-01-26
US63/303,383 2022-01-26
US202263304042P 2022-01-28 2022-01-28
US63/304,042 2022-01-28
US202263334071P 2022-04-22 2022-04-22
US202263334065P 2022-04-22 2022-04-22
US63/334,065 2022-04-22
US63/334,071 2022-04-22
US202263340304P 2022-05-10 2022-05-10
US202263340292P 2022-05-10 2022-05-10
US63/340,304 2022-05-10
US63/340,292 2022-05-10
US202263342509P 2022-05-16 2022-05-16
US63/342,509 2022-05-16
US202263348908P 2022-06-03 2022-06-03
US63/348,908 2022-06-03
PCT/US2023/011651 WO2023146984A1 (en) 2022-01-26 2023-01-26 Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment

Publications (1)

Publication Number Publication Date
KR20240142470A true KR20240142470A (ko) 2024-09-30

Family

ID=87472560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247027934A Pending KR20240142470A (ko) 2022-01-26 2023-01-26 지방산의 림프 방출 조성물 및 림프 혼입과 전신 질환 치료를 위한 이의 용도

Country Status (10)

Country Link
US (1) US20240165066A1 (https=)
EP (1) EP4468884A4 (https=)
JP (1) JP2025503961A (https=)
KR (1) KR20240142470A (https=)
AU (1) AU2023213684A1 (https=)
CA (1) CA3248854A1 (https=)
IL (1) IL314467A (https=)
MA (1) MA66915A1 (https=)
MX (1) MX2024009147A (https=)
WO (1) WO2023146984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3278665T (pt) * 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
US12433864B2 (en) 2019-06-03 2025-10-07 Migal Galilee Research Institute Ltd. 5,6-diHETE lactone for treatment of microvascular dysfunction
GB202400712D0 (en) * 2024-01-18 2024-03-06 Northwood Consultants Ltd Anti-inflammatory composition and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) * 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
US6077525A (en) * 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
JP2005529728A (ja) * 2002-06-18 2005-10-06 マーテック・バイオサイエンシーズ・コーポレーション 水溶液中の油の安定エマルジョンおよびその製造方法
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
ATE549014T1 (de) * 2006-09-05 2012-03-15 Q P Corp Prostaglandin-fettemulsion, verfahren zu ihrer herstellung, verfahren zu ihrer stabilisierung und emulgierendes mittel
WO2011060084A1 (en) * 2009-11-10 2011-05-19 MyCell Holdings Limited Stabilized formulations of fatty acids
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
MX372724B (es) * 2012-12-24 2020-06-19 Qualitas Health Inc Formulaciones de acido eicosapentaenoico (epa).
MY185428A (en) * 2015-01-21 2021-05-19 Mochida Pharm Co Ltd Self-emulsifying composition of ?-3 fatty acid
CA2974495C (en) * 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
JP6783891B2 (ja) * 2019-04-10 2020-11-11 持田製薬株式会社 ω３脂肪酸の自己乳化組成物

Also Published As

Publication number Publication date
US20240165066A1 (en) 2024-05-23
IL314467A (en) 2024-09-01
EP4468884A4 (en) 2025-12-10
EP4468884A1 (en) 2024-12-04
AU2023213684A1 (en) 2024-08-15
MX2024009147A (es) 2024-08-06
CA3248854A1 (en) 2023-08-03
MA66915A1 (fr) 2025-10-31
JP2025503961A (ja) 2025-02-06
WO2023146984A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
KR20240142470A (ko) 지방산의 림프 방출 조성물 및 림프 혼입과 전신 질환 치료를 위한 이의 용도
Harris et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives
US11141399B2 (en) Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US10973797B2 (en) Methods of reducing apolipoprotein c-III
US11285127B2 (en) Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Braeckman et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)
CN113164426A (zh) 用于治疗或预防由暴露于空气污染引起的疾病和/或病症的组合物和方法
US20150073050A1 (en) Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
US20150250757A1 (en) Methods for treating hypertriglyceridemia
CN108096235A (zh) 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
KR20140007973A (ko) 고중성지방혈증 치료 방법
CN118714935A (zh) 淋巴释放的脂肪酸组合物以及其用于淋巴并入和全身性疾病治疗的用途
HK40056640A (en) Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
AU2018274854A1 (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000